(2-methoxyphenyl)(pyridine-2-yl)methanamine | 95899-01-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (2-methoxyphenyl)(pyridine-2-yl)methanamine
• 英文别名: (2-Methoxyphenyl)(pyridin-2-yl)methanamine；(2-methoxyphenyl)-pyridin-2-ylmethanamine
• CAS: 95899-01-7
• 化学式: C₁₃H₁₄N₂O
• mdl: MFCD12153918
• 分子量: 214.267
• InChiKey: ZJWYEBFUZYOBGI-UHFFFAOYSA-N

物化性质

• 沸点：
  362.4±37.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2-methoxyphenyl)(pyridine-2-yl)methanamine 以 乙醇 为溶剂， 生成 1-Cyano-3-[(2-methoxyphenyl)-pyridin-2-ylmethyl]-2-methylguanidine
  参考文献：
  名称：

  N-氰基-N'-（苯基-吡啶基甲基）胍衍生物的合成和胃抗分泌活性。

  摘要：

  N-烷基-N'-氰基-N"-(取代苯基吡啶甲基)胍衍生物被合成并测试了对大鼠胃分泌的抑制活性。合成的化合物中，有几个展现了对基础胃分泌的抑制活性，与西咪替丁相当，但在对抗组胺刺激的胃分泌方面，活性不如西咪替丁。还讨论了一些结构-活性关系。

  DOI：

  10.1248/cpb.32.4893
• 作为产物：
  描述：

  2-氰基吡啶 、 2-Methoxyphenylmagnesium bromide 在 异丁醇 、 sodium tetrahydroborate 、 水 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 1.0h， 以95%的产率得到(2-methoxyphenyl)(pyridine-2-yl)methanamine
  参考文献：
  名称：

  [EN] IMIDAZOPYRIDINE DERIVATIVES AS BSR-3 ANTAGONISTS
  [FR] DERIVES D'IMIDAZOPYRIDINE ANTAGONISTES DE BSR-3

  摘要：

  通式（I）的化合物：其中X、Y、R和R'如规范中描述。还包括包含这些化合物的药物组合物、其制备方法，以及利用这些化合物制备用于治疗BRS-3受体相关疾病的药物的用途。

  公开号：

  WO2005080390A1

文献信息

• [EN] DOPAMINE D2 RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR D2 DE LA DOPAMINE
  申请人：BROAD INST INC

  公开号：WO2016100823A1

  公开（公告）日：2016-06-23

  The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

  本发明涉及新型多巴胺D2受体配体。本发明进一步涉及功能偏倚的多巴胺D2受体配体以及利用这些化合物治疗或预防与多巴胺活性失调相关的中枢神经系统和全身性疾病。
• Dopamine D2 receptor ligands
  申请人：The Broad Institute, Inc.

  公开号：US10752588B2

  公开（公告）日：2020-08-25

  The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

  本发明涉及新型多巴胺D2受体配体。本发明还涉及具有功能偏倚的多巴胺 D2 受体配体，以及使用这些化合物治疗或预防与多巴胺能活性失调有关的中枢神经系统和全身性疾病。
• Inhibition of Insulin-Regulated Aminopeptidase by Imidazo [1,5-α]pyridines—Synthesis and Evaluation
  作者：Karin Engen、Thomas Lundbäck、Anubha Yadav、Sharathna Puthiyaparambath、Ulrika Rosenström、Johan Gising、Annika Jenmalm-Jensen、Mathias Hallberg、Mats Larhed

  DOI：10.3390/ijms25052516

  日期：——

  Inhibition of insulin-regulated aminopeptidase (IRAP) has been shown to improve cognitive functions in several animal models. Recently, we performed a screening campaign of approximately 10,000 compounds, identifying novel small-molecule-based compounds acting as inhibitors of the enzymatic activity of IRAP. Here we report on the chemical synthesis, structure-activity relationships (SAR) and initial

  在多种动物模型中，抑制胰岛素调节氨肽酶 (IRAP) 已被证明可以改善认知功能。最近，我们对大约 10,000 种化合物进行了筛选，鉴定了作为 IRAP 酶活性抑制剂的新型小分子化合物。在此，我们报告了一系列 48 种咪唑并[1,5-α]吡啶类抑制剂的化学合成、构效关系 (SAR) 和理化性质的初步表征，包括将其作用模式描述为非竞争性具有基于 L-亮氨酸的小型 IRAP 底物的抑制剂。最佳化合物的 IC50 值为 1.0 µM。我们阐明了这些分子中两个手性位点的重要性，发现它们对化合物的代谢稳定性或理化性质影响很小。中心脲部分的羰基最初被认为模拟底物与活性位点中催化重要的 Zn2+ 离子的结合，尽管这种结合假设的合理性因观察到与密切相关的氨肽酶 N (APN) 相比具有优异的选择性而受到挑战。与非竞争性抑制模式一起，我们还考虑了变构结合的替代模型。
• Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule Screening
  作者：Karin Engen、Ulrika Rosenström、Hanna Axelsson、Vivek Konda、Leif Dahllund、Magdalena Otrocka、Kristmundur Sigmundsson、Alexandros Nikolaou、Georges Vauquelin、Mathias Hallberg、Annika Jenmalm Jensen、Thomas Lundbäck、Mats Larhed

  DOI：10.1089/adt.2016.708

  日期：2016.4

  Intracerebroventricular injection of angiotensin IV, a ligand of insulin-regulated aminopeptidase (IRAP), has been shown to improve cognitive functions in several animal models. Consequently, IRAP is considered a potential target for treatment of cognitive disorders. To identify nonpeptidic IRAP inhibitors, we adapted an established enzymatic assay based on membrane preparations from Chinese hamster ovary cells and a synthetic peptide-like substrate for high-throughput screening purposes. The 384-well microplate-based absorbance assay was used to screen a diverse set of 10,500 compounds for their inhibitory capacity of IRAP. The assay performance was robust with Z-values ranging from 0.81 to 0.91, and the screen resulted in 23 compounds that displayed greater than 60% inhibition at a compound concentration of 10M. After hit confirmation experiments, purity analysis, and promiscuity investigations, three structurally different compounds were considered particularly interesting as starting points for the development of small-molecule-based IRAP inhibitors. After resynthesis, all three compounds confirmed low M activity and were shown to be rapidly reversible. Additional characterization included activity in a fluorescence-based orthogonal assay and in the presence of a nonionic detergent and a reducing agent, respectively. Importantly, the characterized compounds also showed inhibition of the human ortholog, prompting our further interest in these novel IRAP inhibitors.
• SHIMADA, KATSUTOSHI;FUJISAKI, HIDEAKI;OKETANI, KIYOSHI;MURAKAMI, MANABU;S+, CHEM. AND PHARM. BULL., 1984, 32, N 12, 4893-4906
  作者：SHIMADA, KATSUTOSHI、FUJISAKI, HIDEAKI、OKETANI, KIYOSHI、MURAKAMI, MANABU、S+

  DOI：——

  日期：——